What's in Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s pipeline?

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has 115 drugs in our index: 11 marketed, 0 filed, 32 in Phase 3, 18 in Phase 2, 54 in Phase 1.

Which companies overlap with Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sun Yat-sen University, Merck Sharp & Dohme LLC, Pfizer, GlaxoSmithKline, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chia-tai-tianqing-pharmaceutical-group-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. pipeline: 11 marketed, 0 filed, 32 Phase 3, 18 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 32 Phase 3 18 Phase 2 54 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Spiriva HandiHaler	Spiriva HandiHaler	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic acetylcholine receptor	Respiratory
blank Baraclude tablets	blank Baraclude tablets	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase	Virology / Hepatology
Spiriva®Handihaler®	Spiriva®Handihaler®	marketed
Anlotinib hydrochloride capsules	Anlotinib hydrochloride capsules	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, PDGFR, c-Kit, RET	Oncology
Dasatinib Tablets	Dasatinib Tablets	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases	Oncology
Blank maleate entecavir tablets	Blank maleate entecavir tablets	marketed	Nucleoside reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase	Virology / Hepatology
Entecavir Tablet	Entecavir Tablet	marketed
Obeticholic Acid Tablets	Obeticholic Acid Tablets	marketed
Baraclude tablets	Baraclude tablets	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase	Virology / Hepatology
Carboplatin Injection	Carboplatin Injection	marketed	Platinum-based chemotherapy agent	DNA	Oncology
Tresiba®	Tresiba®	marketed	Basal insulin analog	Insulin receptor	Diabetes
Docetaxel injection	Docetaxel injection	phase 3	Taxane (microtubule stabilizer)	β-tubulin / microtubules	Oncology

Therapeutic area mix

Oncology · 26
Infectious Disease · 4
Virology / Hepatology · 3
Other · 3
Respiratory · 2
Diabetes · 2
Cardiovascular; Critical Care · 1
Cardiovascular / Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sun Yat-sen University · 6 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
Pfizer · 5 shared drug classes
GlaxoSmithKline · 5 shared drug classes
AstraZeneca · 5 shared drug classes
Eli Lilly and Company · 5 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 4 shared drug classes
Assistance Publique - Hôpitaux de Paris · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Chia Tai Tianqing Pharmaceutical Group Co., Ltd.:

Cite this brief

Drug Landscape (2026). Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chia-tai-tianqing-pharmaceutical-group-co-ltd. Accessed 2026-05-17.